Clinical Trials

A Multicenter Phase 1 Study to Determine the Safety and Efficacy of Multiple Doses at Defined Intervals of Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Administered via Intraventricular Catheter for Any Primary Solid Tumor Cancer with Lep

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Andrew Brenner, MD, PhD

For more information about this study
View Details

About This Study

This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.